These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32103551)

  • 41. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy.
    Lee H; Jin GY; Han YM; Chung GH; Lee YC; Kwon KS; Lynch D
    Cardiovasc Intervent Radiol; 2012 Apr; 35(2):343-50. PubMed ID: 21626257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry.
    Lara JD; Brunson A; Riess JW; Kelly K; Lara PN; Gandara DR
    Lung Cancer; 2017 Oct; 112():165-168. PubMed ID: 29191590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations.
    Asamura H; Goya T; Koshiishi Y; Sohara Y; Tsuchiya R; Miyaoka E;
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):316-9. PubMed ID: 16872956
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
    Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological characteristics and surgical results of lung cancer patients aged up to 50 years: the Japanese Lung Cancer Registry Study 2004.
    Inoue M; Okumura M; Sawabata N; Miyaoka E; Asamura H; Yoshino I; Tada H; Fujii Y; Nakanishi Y; Eguchi K; Mori M; Kobayashi H; Yokoi K
    Lung Cancer; 2014 Feb; 83(2):246-51. PubMed ID: 24296124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lung cancer prognosis before and after recurrence in a population-based setting.
    Consonni D; Pierobon M; Gail MH; Rubagotti M; Rotunno M; Goldstein A; Goldin L; Lubin J; Wacholder S; Caporaso NE; Bertazzi PA; Tucker MA; Pesatori AC; Landi MT
    J Natl Cancer Inst; 2015 Jun; 107(6):djv059. PubMed ID: 25802059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonsmall cell lung cancer: evaluation of 737 consecutive patients in a single institution.
    Younes RN; Deutsch F; Badra C; Gross J; Haddad F; Deheinzelin D
    Rev Hosp Clin Fac Med Sao Paulo; 2004 Jun; 59(3):119-27. PubMed ID: 15286831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostically orientated multimodality treatment including surgery for selected patients of small-cell lung cancer patients stages IB to IIIB: long-term results of a phase II trial.
    Eberhardt W; Stamatis G; Stuschke M; Wilke H; Müller MR; Kolks S; Flasshove M; Schütte J; Stahl M; Schlenger L; Budach V; Greschuchna D; Stüben G; Teschler H; Sack H; Seeber S
    Br J Cancer; 1999 Dec; 81(7):1206-12. PubMed ID: 10584883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of pneumonectomy for non-small cell lung cancer: appropriateness of the new TNM staging system.
    Mizushima Y; Noto H; Kusajima Y; Sugiyama S; Yamashita R; Sassa K; Kobayashi M
    Oncol Rep; 1998; 5(2):437-40. PubMed ID: 9468575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
    Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
    Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment and prognosis of advanced stage non-small-cell lung cancer].
    Chermiti Ben Abdallah F; Ben Ali G; Sadok Boudaya M; Mlika M; Chtourou A; Taktak S; Ben Kheder A
    Rev Mal Respir; 2014 Mar; 31(3):214-20. PubMed ID: 24680112
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
    Franco F; Carcereny E; Guirado M; Ortega AL; López-Castro R; Rodríguez-Abreu D; García-Campelo R; Del Barco E; Juan O; Aparisi F; González-Larriba JL; Domine M; Trigo JM; Cobo M; Cerezo S; Calzas J; Massutí B; Bosch-Barrera J; García Coves P; Domènech M; Provencio M
    PLoS One; 2021; 16(6):e0251761. PubMed ID: 34077442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lung Cancer in the Oldest Old: A Nation-Wide Study in The Netherlands.
    Schulkes KJG; Pouw CAM; Driessen EJM; van Elden LJR; van den Bos F; Janssen-Heijnen MLG; Lammers JJ; Hamaker ME
    Lung; 2017 Oct; 195(5):627-634. PubMed ID: 28631153
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
    Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution.
    Kameyama K; Takahashi M; Ohata K; Igai H; Yamashina A; Matsuoka T; Nakagawa T; Okumura N
    J Thorac Cardiovasc Surg; 2009 May; 137(5):1180-4. PubMed ID: 19379988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.